{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T11:04:37Z","timestamp":1766487877130,"version":"3.48.0"},"reference-count":24,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Viral infections have shaped human history since the earliest stages of civilization and continue to exert one of the greatest global pressures on health, socioeconomic stability, and public health infrastructures [...]<\/jats:p>","DOI":"10.3390\/v18010020","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T10:57:18Z","timestamp":1766487438000},"page":"20","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent Advances in Anti-HCV, Anti-HBV and Anti-Flavivirus Agents"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9442-5186","authenticated-orcid":false,"given":"Grigoris","family":"Zoidis","sequence":"first","affiliation":[{"name":"Division of Pharmaceutical Chemistry, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Panepistimiopolis-Zografou, 15771 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024). Global Hepatitis Report 2024, WHO."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection: A systematic review","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: A Lancet Gastroenterology & Hepatology Commission","volume":"4","author":"Cooke","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1473-3099(16)00026-8","article-title":"The global burden of dengue: An analysis from the Global Burden of Disease Study 2013","volume":"16","author":"Stanaway","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(18)32560-1","article-title":"Dengue","volume":"393","author":"Ooi","year":"2019","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1602113","article-title":"Zika Virus","volume":"374","author":"Petersen","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/v6020606","article-title":"Clinical manifestations and outcomes of West Nile virus infection","volume":"6","author":"Sejvar","year":"2014","journal-title":"Viruses"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0065-3527(03)60009-6","article-title":"Pathogenesis and pathophysiology of Yellow Fever","volume":"60","author":"Monath","year":"2003","journal-title":"Adv. Virus Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrd.2017.33","article-title":"Broad-spectrum agents for flaviviral infections: Dengue, Zika and beyond","volume":"16","author":"Boldescu","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_11","unstructured":"World Health Organization (2023). Prioritizing Diseases for Research and Development in Emergency Contexts, WHO."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Giannakopoulou, E., Akrani, I., Mpekoulis, G., Frakolaki, E., Dimitriou, M., Myrianthopoulos, V., Vassilaki, N., and Zoidis, G. (2024). Novel Pyrazino[1,2-a]indole-1,3(2H,4H)-dione Derivatives Targeting the Replication of Flaviviridae Viruses: Structural and Mechanistic Insights. Viruses, 16.","DOI":"10.3390\/v16081238"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Nasr, T., Aboshanab, A.M., Mpekoulis, G., Drakopoulos, A., Vassilaki, N., Zoidis, G., Abouzid, K.A.M., and Zaghary, W. (2022). Novel 6-Aminoquinazolinone Derivatives as Potential Cross GT1-4 HCV NS5B Inhibitors. Viruses, 14.","DOI":"10.3390\/v14122767"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Olenginski, L.T., Attionu, S.K., Henninger, E.N., LeBlanc, R.M., Longhini, A.P., and Dayie, T.K. (2023). Hepatitis B Virus Epsilon (\u03b5) RNA Element: Dynamic Regulator of Viral Replication and Attractive Therapeutic Target. Viruses, 15.","DOI":"10.3390\/v15091913"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Nayak, S., Gowda, J., Abbas, S.A., Kim, H., and Han, S.B. (2023). Recent Advances in the Development of Sulfamoyl-Based Hepatitis B Virus Nucleocapsid Assembly Modulators. Viruses, 15.","DOI":"10.3390\/v15122367"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kasianchuk, N., Dobrowolska, K., Harkava, S., Bretcan, A., Zar\u0119bska-Michaluk, D., Jaroszewicz, J., Flisiak, R., and Rzymski, P. (2023). Gene-Editing and RNA Interference in Treating Hepatitis B: A Review. Viruses, 15.","DOI":"10.3390\/v15122395"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Guo, J., Mi, Y., Guo, Y., Bai, Y., Wang, M., Wang, W., and Wang, Y. (2024). Current Advances in Japanese Encephalitis Virus Drug Development. Viruses, 16.","DOI":"10.3390\/v16020202"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Van Gulck, E., Concei\u00e7\u00e3o-Neto, N., Aerts, L., Pierson, W., Verschueren, L., Vleeschouwer, M., Krishna, V., N\u00e1jera, I., and Pauwels, F. (2024). Retreatment with HBV siRNA Results in Additional Reduction in HBV Antigenemia and Immune Stimulation in the AAV-HBV Mouse Model. Viruses, 16.","DOI":"10.3390\/v16030347"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Androutsakos, T., Tsantzali, I., Karagiannakis, D.S., Flevari, P., Iakovou, D., Pouliakis, A., Kykalos, S., Doris, S., and Xyla, V. (2024). Peripheral Neuropathy in Patients with Hepatitis C Infection\u2014Reversibility after HCV Eradication: A Single Center Study. Viruses, 16.","DOI":"10.3390\/v16040522"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Quaranta, M.G., Cavalletto, L., Russo, F.P., Calvaruso, V., Ferrigno, L., Zanetto, A., Mattioli, B., D\u2019Ambrosio, R., Panetta, V., and Brancaccio, G. (2024). Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV). Viruses, 16.","DOI":"10.3390\/v16050682"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Iman, K., Mirza, M.U., Sadia, F., Froeyen, M., Trant, J.F., and Chaudhary, S.U. (2024). Pharmacophore-Assisted Covalent Docking Identifies a Potential Covalent Inhibitor for Drug-Resistant Genotype 3 Variants of Hepatitis C Viral NS3\/4A Serine Protease. Viruses, 16.","DOI":"10.20944\/preprints202407.1116.v1"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lin, Y.-F., Lai, H.-C., Lin, C.-S., Hung, P.-Y., Kan, J.-Y., Chiu, S.-W., Lu, C.-H., Petrova, S.F., Baltina, L., and Lin, C.-W. (2024). Discovery of Potent Dengue Virus NS2B-NS3 Protease Inhibitors Among Glycyrrhizic Acid Conjugates with Amino Acids and Dipeptides Esters. Viruses, 16.","DOI":"10.3390\/v16121926"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Grabski, H., Grabska, S., and Abagyan, R. (2025). Identifying Allosteric Small-Molecule Binding Sites of Inactive NS2B-NS3 Proteases of Pathogenic Flaviviridae. Viruses, 17.","DOI":"10.3390\/v17010006"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/1\/20\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T11:01:52Z","timestamp":1766487712000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/1\/20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["v18010020"],"URL":"https:\/\/doi.org\/10.3390\/v18010020","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]}}}